You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Induction of systemic and therapeutic antitumor immunity using intratumoral injection of bone-marrow derived dendritic cells genetically modified to express interleukin 12 combined with anti-CTLA-4 antibody

Article Text

Article menu

Download PDFPDF

Poster Presentation
Induction of systemic and therapeutic antitumor immunity using intratumoral injection of bone-marrow derived dendritic cells genetically modified to express interleukin 12 combined with anti-CTLA-4 antibody
  1. Marimo Sato-Matsushita1,
  2. Yoshihiro Hayakawa2,
  3. Asuka Asami1,
  4. Setsuko Nakayama1 and
  5. Hideaki Tahara1
  1. Aff1 grid.26999.3d000000012151536XThe University of Tokyo Minato-city Japan
  2. Aff2 grid.267346.2000000012171836XThe University of Toyama Toyama-city Japan

https://doi.org/10.1186/2051-1426-3-S2-P243

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    We have been involved in the development of cancer immunotherapy using dendritic cells (DCs) manipulated to induce better immune responses. Our strategies include the usage of the agent to induce desirable maturation of DCs in culture and the genetic modification of DCs to have better function in situ. We have been developing immune-gene therapy with DCs genetically modified to continuously express IL-12. In this study, we investigated whether bone marrow-derived dendritic cells adenovirally transduced with genes encoding murine IL-12 combined with anti-CTLA-4 monoclonal antibody (Ad-IL-12-DCs) have significant therapeutic benefits for anti-tumor immunotherapy. Ad-IL-12-DCs was confirmed to express bioactive IL-12 proteins at high levels, and treatment with Ad-IL-12-DCs and anti-CTLA-4 monoclonal antibody showed enhanced anti-tumor effects and induced tumor-specific cytotoxic T lymphocyte responses in vivo. As a consequence of these stimulatory effects, combined treatment with DC vaccine and anti-CTLA-4 monoclonal antibody accomplished increased anti-tumor effects when compared with either mono-therapy. The information related to these trials would be useful to develop effective immunotherapy against cancer.